In this case, I am analyzing the financing plan of Purinex Inc.. I need to determine what is the best financial alternative for the company in order to set up a partnership with a large pharmaceutical laboratory. Purinex feels there is a chance to partner with a larger company in the next four to 12 months. There is, however, a big problem. Purinex only has funds to last about eleven months. The CFO of Purinex believes that if a partnership is concluded, the deal could lead the company to achieve its main goal, which is to develop drugs for the diseases of sepsis and diabetes. Purinex faces the challenge of running out of money if a partnership is not concluded in time. In order to address this challenge, Harpaz is faced with three options that could solve the problem. In the following article, I discuss the situation, followed by an analysis of each of the three options “venture round option”, “six month wait option”. , and “angel round option”. Finally, I make my recommendation which is the “angel round option”. I decided to go with the angel round option for several reasons. I believe this is the safest option among the three and gives Purinex the best opportunity to partner with a large company before losing its valuation within the company. Plus, there aren't as many restrictions and the $2 million from angel investors gives the company a little more leeway. Additionally, this approach carries much less risk. Situation Analysis: Purinex is a pharmaceutical drug discovery and development company that wanted to commercialize wound healing compounds based on its purine drug development platform. The company had 14 employees and a chemistry laboratory. Also, Purinex had an intellect...... middle of paper ...... its options, the round angel option seems to fit the best. The deal with the angel investors would require 6 months to secure the capital injection that would be necessary to maintain operations until a partnership agreement is put in place. I think this is a good option because there is a 95% chance of forming a partnership in the next two years. With this $2 million injection, Purinex will be able to survive until a deal is reached. Additionally, I feel that the angel round option is the best alternative because the valuation of the company will be much higher than the venture capital round option. Additionally, there are not as many controls or restrictions as the venture capital round option. I think it's better than the "option to wait six months" because I feel like the "option to wait six months" is too risky. Receiving just $2 million from angel investors gives Purinex a little more leeway.